This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • New Formulations of Propafenone to Treat Atrial Fi...
Clinical trial

New Formulations of Propafenone to Treat Atrial Fibrillation

Read time: 1 mins
Last updated:1st May 2016

Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction
Estimated Enrollment: 243
Study Start Date: May 2016
Estimated Study Completion Date: March 2020
Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)

- Experimental:
- Active Comparator: (S)-Propafenone
- Placebo Comparator: Placebo

Category Value
Study start date 2016-05-01

View full details